HER2 Support Group Forums - View Single Post - ImmunoGen reports data from T-DM1 Phase III trial on HER2-positive metastatic breast

News · 06-04-2012, 12:01 AM

ImmunoGen, Inc., a biotechnology company with a proprietary Targeted Antibody Payload (TAP) technology, today announced results from the trastuzumab emtansine Phase III EMILIA trial conducted by Roche.

More...

06-04-2012, 12:01 AM	#1
News Senior Member Join Date: Oct 2007 Posts: 19,644	ImmunoGen reports data from T-DM1 Phase III trial on HER2-positive metastatic breast ImmunoGen, Inc., a biotechnology company with a proprietary Targeted Antibody Payload (TAP) technology, today announced results from the trastuzumab emtansine Phase III EMILIA trial conducted by Roche. More...